Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer (Q827694)
From MaRDI portal
!
This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:
scientific article; zbMATH DE number 7294133
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer |
scientific article; zbMATH DE number 7294133 |
Statements
Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer (English)
0 references
13 January 2021
0 references
adoptive T cell transfer
0 references
TCR T cells
0 references
IL-2 treatment
0 references
combination cancer therapy
0 references
mathematical oncology
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0.757251501083374
0 references
0.7572365403175354
0 references
0.7524075508117676
0 references
0.74880051612854
0 references
